Global Gastroparesis Drugs Market Analysis & Industry Forecast 2017-2023, With an Expected CAGR of 4.7% - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 12, 2018--The “Gastroparesis Drugs Market by Drug Class, Disease Type, and End User - Global Opportunity Analysis and Industry Forecast, 2017-2023” report has been added to ResearchAndMarkets.com’s offering.
The global gastroparesis market was valued at $4,667 million in 2016, and is projected to reach $6,486 million at a CAGR of 4.7% from 2017 to 2023.
Gastroparesis is a medical condition of the stomach, which affects the normal spontaneous movement of the muscles of the stomach. It restricts the normal digestion, causes vomiting, and problems related with blood sugar levels & nutrition. Various medications or drugs are prescribed to treat gastroparesis, such as reglan, erythromycin, antiemetics, and others.
Rise in number of surgeries, which leads to postsurgical gastroparesis conditions is the major factor that contributes to the growth of the gastroparesis drugs market. Moreover, rise in diabetic population, increase in geriatric population, and introduction of novel drugs to control symptoms such as nausea and vomiting fuel the market growth. However, side effects related to gastroparesis drugs, time-consuming regulatory process for the approval of drugs, and complications in gastroparesis diagnosis hamper the growth of the market.
The global gastroparesis drugs market is segmented on the basis of drug class, disease type, distribution channel, and region. Based on drug class, the market is divided into prokinetic agents, antiemetic agents, and botulinum toxin injections. By disease type, it is classified into diabetic gastroparesis, idiopathic gastroparesis, postsurgical gastroparesis, and others. Depending on distribution channel, it is categorized into hospitals, pharmacies, clinics, and e-commerce.
Companies Mentioned:Allergan, Plc. Abbott Laboratories (Abbott Arzneimittel GmbH) AstraZeneca Plc. Cadila Pharmaceuticals Ltd. ETX Pharma, Inc Evoke Pharma GlaxoSmithKline Plc. Neurogastrx, Inc. Valeant Pharmaceuticals International, Inc. Theravance Biopharma
Key Topics Covered:
2 Executive Summary
3 Market Overview
4 Gastroparesis Drugs Market, by Drug Class
5 Gastroparesis Drugs Market, by Disease Type
6 Gastroparesis Drugs Market, by Distribution Channel
7 Gastroparesis Drugs Market, by Region
8 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/mlcwhj/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180612005805/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Gastrointestinal Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/12/2018 08:10 AM/DISC: 06/12/2018 08:10 AM